| All | BRCA1 or 2 mutation | |
---|---|---|---|
Yes | No | ||
Patients | 120 | 12 (10Â %) | 108 (90Â %) |
Triple-negative | 20 (17Â %) | 6 (50Â %) | 14 (13Â %)* |
ER&PR positive | 67 (57Â %) | 3 (25Â %) | 64 (61Â %)* |
HER2 positive | 27 (23Â %) | 0 | 27 (26Â %)* |
Histology | Â | Â | Â |
 Invasive Ductal Carcinoma (IDC) | 98 (85 %) | 11 (92 %) | 87 (82 %) |
 Ductal Carcinoma In Situ (DCIS) | 11 (9 %) | 0 | 11 (10 %) |
 Invasive Lobular Carcinoma (ILC) | 4 (3 %) | 0 | 4 (4 %) |
 Other/rare | 4 (3 %) | 1 (8 %) | 3 (3 %) |
Age at diagnosis | 50.6 ± 11.6 | 43.7 ± 11.8 | 51.4 ± 11.3* |
Age at first menses | 12.8 ± 1.6 | 12.3 ± 1.4 | 12.8 ± 1.6 |
Education | Â | Â | Â |
 High school diploma or less | 95 (81 %) | 8 (66 %) | 87 (82 %) |
 Beyond high school | 23 (19 %) | 4 (34 %) | 19 (18 %) |
Household Income | Â | Â | Â |
  < $25,000 | 61 (60 %) | 1 (10 %) | 60 (65 %) |
  > $25,000 | 41 (40 %) | 9 (90 %) | 32 (35 %) |
Family history of BRCA | 42 (35Â %) | 6 (50Â %) | 36 (34Â %) |